Action ARCH ARCH BIOPARTNERS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Arch Biopartners Inc. Toronto S.E.

Actions

ARCH

CA03938C1041

Temps Différé Toronto S.E.
Autres places de cotation
 15:38:30 16/07/2024 		Varia. 5j. Varia. 1 janv.
1,63 CAD +0,31 % Graphique intraday de Arch Biopartners Inc. -1,21 % +10,14 %
27/06 Arch Biopartners en hausse de plus de 2% après l'annonce de la fabrication GMP d'un médicament à base de cilastatine MT
27/06 Arch Biopartners Inc. annonce la fabrication d'un produit pharmaceutique à base de cilastatine selon les bonnes pratiques de fabrication (BPF) CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Arch Biopartners Inc. - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ACHFF
  4. Action ARCH
  5. Actualités Arch Biopartners Inc.
  6. Autres langues